Welcome to our dedicated page for Alamar Biosciences SEC filings (Ticker: ALMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Alamar Biosciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Alamar Biosciences's regulatory disclosures and financial reporting.
Alamar Biosciences director Witney Frank has reported existing stock option holdings for Class B Common Stock. The filing lists three option awards with exercise prices of $0.59, $3.10 and $7.60 per share, covering 49,627, 33,085 and 124,069 underlying shares, expiring between 2031 and 2036.
Footnotes state that one option is fully vested, while others vest in monthly installments over 48 months, with a portion beginning to vest on January 15, 2027 and another measured from January 1, 2025, contingent on continuous service.
Alamar Biosciences, Inc. director Ian W. Ratcliffe filed a Form 3 as an initial statement of his ownership status in company securities. The filing lists him as a director of Alamar Biosciences, Inc. (ticker ALMR) and reports no transactions or derivative positions at this time.
Alamar Biosciences director Rebecca Chambers reported her initial holdings of stock options in the company. The Form 3 shows a stock option covering 140,612 shares of Class B Common Stock with an exercise price of $7.60 per share and an expiration date of January 14, 2036.
According to the filing, 25% of the shares subject to the option vest on January 15, 2027, and the remaining shares vest in equal monthly installments over the following three years, contingent on her continued service with the company. This is a routine disclosure of an equity award rather than a new market transaction.
Alamar Biosciences director Nicholas Naclerio filed an initial Form 3 showing indirect interests in Illumina-affiliated investment funds that hold Alamar securities. The filing lists convertible promissory notes and multiple preferred stock series that are all convertible into Alamar equity.
The Series A-3, Series A-4 and Series C Preferred Stock are each convertible into Class B Common Stock on a 1-for-2.418 basis at the holder’s election and will automatically convert into common stock upon the closing of Alamar’s initial public offering. The Series B Preferred Stock converts into Class B Common Stock on a 1-for-2.271 basis with the same automatic IPO conversion feature.
The filing also describes a convertible note maturing on July 8, 2027, which will automatically convert, together with accrued interest, into common stock at a price equal to 85% of the IPO price. All securities are held by Illumina Innovation Fund II, L.P. and Illumina Innovation Fund III, L.P.; their general partners and Naclerio may be deemed to share voting and investment power but each disclaims beneficial ownership except for any pecuniary interest.
Alamar Biosciences, Inc. Chief Financial Officer Justin J. McAnear reported his initial holdings of a stock option to buy Class B common stock. The option covers 570,719 underlying shares at an exercise price of $4.62 per share and expires on October 14, 2035.
According to the vesting terms, 25% of the shares subject to the option vest on October 13, 2026, and 1/48th of the shares vest monthly thereafter, as long as McAnear continues providing service through each vesting date.
Alamar Biosciences, Inc. President Timothy Ogden White filed an initial ownership report showing direct holdings of 454,583 shares of Class B Common Stock. He also reports multiple stock options to buy Class B Common Stock, with exercise prices ranging from $0.59 to $7.60 per share and expirations between 2031 and 2036, many vesting in equal monthly installments over 48 months, subject to his continuous service.
Alamar Biosciences, Inc. Chief Executive Officer Luo Yuling filed an initial statement of beneficial ownership, listing existing share and option positions as of April 16, 2026. The filing shows direct and indirect holdings of Class A and Class B Common Stock, preferred stock, and multiple vested and time-vesting stock options.
Alamar Biosciences, Inc. is conducting an initial public offering of 9,375,000 shares of common stock, with an expected price range of $15.00 to $17.00 per share, and has granted underwriters a 30-day option to buy up to 1,406,250 additional shares.
The company seeks to list on the Nasdaq Global Select Market under the symbol “ALMR.” Alamar is a commercial-stage proteomics company built around its proprietary NULISA technology and ARGO HT instruments, targeting ultra-sensitive, multiplex protein detection for research and future diagnostics.
Revenue grew from $25.1 million in 2024 to $74.2 million in 2025, a 195% increase, while gross margin improved from 34% to 56%. The company remains unprofitable, with net losses of $47.1 million in 2024 and $29.8 million in 2025, and expects Q1 2026 revenue between $25.2 million and $26.2 million.